Yes-associated protein regulates the hepatic response after bile duct ligation

• Published in: Hepatology (Baltimore, Md.) Vol. 56; no. 3; pp. 1097 - 1107
• Main Authors: Bai, Haibo, Zhang, Nailing, Xu, Yang, Chen, Qian, Khan, Mehtab, Potter, James J., Nayar, Suresh K., Cornish, Toby, Alpini, Gianfranco, Bronk, Steven, Pan, Duojia, Anders, Robert A.
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.09.2012; Wiley; Wiley Subscription Services, Inc
• Subjects: Animals; Bile; Bile Ducts - cytology; Biological and medical sciences; Cholestasis - complications; Gallbladder diseases; Gastroenterology. Liver. Pancreas. Abdomen; Hepatocytes - physiology; Hepatology; Humans; Ligation; Liver; Liver Injury/Regeneration; Liver Regeneration; Liver. Biliary tract. Portal circulation. Exocrine pancreas; Male; Medical sciences; Mice; Proto-Oncogene Proteins c-yes - physiology; Rodents; Biliary tract; Regulation(control); Hepatic duct; Protein; Gastroenterology
• ISSN: 0270-9139; 1527-3350
• DOI: 10.1002/hep.25769

Human chronic cholestatic liver diseases are characterized by cholangiocyte proliferation, hepatocyte injury, and fibrosis. Yes‐associated protein (YAP), the effector of the Hippo tumor‐suppressor pathway, has been shown to play a critical role in promoting cholangiocyte and hepatocyte proliferation and survival during embryonic liver development and hepatocellular carcinogenesis. Therefore, the aim of this study was to examine whether YAP participates in the regenerative response after cholestatic injury. First, we examined human liver tissue from patients with chronic cholestasis. We found more‐active nuclear YAP in the bile ductular reactions of primary sclerosing cholangitis and primary biliary cirrhosis patient liver samples. Next, we used the murine bile duct ligation (BDL) model to induce cholestatic liver injury. We found significant changes in YAP activity after BDL in wild‐type mice. The function of YAP in the hepatic response after BDL was further evaluated with liver‐specific Yap conditional deletion in mice. Ablating Yap in the mouse liver not only compromised bile duct proliferation, but also enhanced hepatocyte necrosis and suppressed hepatocyte proliferation after BDL. Furthermore, primary hepatocytes and cholangiocytes isolated from Yap‐deficient livers showed reduced proliferation in response to epidermal growth factor in vitro. Finally, we demonstrated that YAP likely mediates its biological effects through the modulation of Survivin expression. Conclusion: Our data suggest that YAP promotes cholangiocyte and hepatocyte proliferation and prevents parenchymal damage after cholestatic injury in mice and thus may mediate the response to cholestasis‐induced human liver disease. (HEPATOLOGY 2012;56:1097–1107)